Glenmark Launches GLIPIQ Semaglutide in India, Targets Affordable GLP-1 Therapy Access

Glenmark Pharmaceuticals has launched GLIPIQ, a semaglutide-based therapy for Type 2 diabetes management in India, positioning it as a more affordable entry point into the GLP-1 treatment segment, the company said in a press release. 

The company said high costs and complexity often delay adoption of injectable therapies. With GLIPIQ, it is looking to enable earlier treatment initiation across a wider patient base by lowering entry barriers.

The drug is available in both vial and pre-filled pen formats. The vial-based option comes with dose-specific syringes, allowing flexible, physician-guided dosing, particularly in early-stage treatment. The company added that this format provides a more cost-effective pathway, supporting better access and adherence.

The weekly treatment cost for the vial format is expected to range between ₹325.0 and ₹440.0, positioning it as a more affordable option within the GLP-1 therapy segment in India.

GLIPIQ has been approved by the Central Drugs Standard Control Organisation following a Phase III clinical study conducted in India, which demonstrated favourable efficacy and safety outcomes in patients with Type 2 diabetes.

The pre-filled pen format is aimed at improving convenience for long-term self-administration. Both vial and pen formats are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL, supporting a structured treatment pathway and continuity of care.

Glenmark is also launching ‘Sankalp’, a patient support programme designed to assist therapy initiation, improve comfort with injectable treatment, and enhance long-term adherence.